Speak with an Advisor

Sell Your Blood & Tissue Banks Business to the Right Buyer

Confidential lower-middle-market M&A advisory, verified valuation benchmarks, and institutional acquirer access for Blood & Tissue Banks company owners.

Schedule a Free Consultation ✦ Free AI Valuation Tool

Why Selling a Blood & Tissue Banks Company Demands Industry-Specific M&A Advisory

 20+ 

Years in M&A Advisory

50

States Served Nationwide 

$1M–$250M 

Revenue Range We Serve 

In-House 

CPA, Legal, & Capital Advisory 

Why Selling a Blood & Tissue Banks Company Demands Industry-Specific M&A Advisory

Operating an established Blood & Tissue Banks business involves managing specialized clinical care, commercial and government payer reimbursements, regulatory accreditations, and provider scheduling. Business owners balance day-to-day project execution margins with client retention and skilled workforce management. Strategic acquirers actively target companies in this sector because reliable operations generate predictable cash flow and established market share.

Qualified corporate buyers prioritize favorable commercial payer mix, clean billing compliance audits, high patient retention, and mid-level provider autonomy. At Aria Business Advisors, we articulate your operational strengths, recast discretionary earnings, and confidentially market your company to vetted strategic acquirers to secure top valuation multiples.

Blood & Tissue Banks Business Valuation & Exit Strategy Guide

Who Buys Blood & Tissue Banks Businesses

The Blood & Tissue Banks M&A market is active. Knowing which buyer type fits your business determines how you position it and how much you walk away with.

Strategic Healthcare Consolidators

Regional health systems, multi-site clinical networks, and strategic healthcare groups acquiring Blood & Tissue Banks operations to expand patient access, payer contracts, and specialty capabilities.
Strategic Healthcare Consolidators Acquiring Blood & Tissue Banks Companies
Healthcare Private Equity Platforms Investing in Blood & Tissue Banks Businesses

Healthcare Private Equity Platforms

Healthcare-focused private equity funds investing in compliant Blood & Tissue Banks platforms with strong commercial payer mix, clinical autonomy, and multi-provider growth potential.

Healthcare Search Funds & Clinical Operators

Healthcare executives, physician-led investment groups, and search funds seeking established Blood & Tissue Banks practices with strong clinical reputation and recurring patient volume.
Healthcare Search Funds & Clinical Operators Buying Blood & Tissue Banks Operations

We run a strictly confidential, controlled process. We screen out window-shoppers so you only engage with well-capitalized, qualified acquirers. Every buyer is rigorously vetted for financial capacity and strategic fit. Your sensitive data is never disclosed without a signed NDA and explicit approval. 

Blood & Tissue Banks M&A Valuation Multiples & Benchmark

Aria M&A Transaction Database • Updated for 2026 Transactions

NAICS 621991 (Blood and Organ Banks) SIC 8099 (Health and Allied Services, NEC)
100% Confidential • In-House CPA & M&A Advisory • Instant AI Estimate
EBITDA Multiple Mid-Market
19.75x Median Multiple
15.8x Low 25.68x High
SDE Multiple SMB / Owner-Led
2.8x Median Multiple
2x Low 3.8x High
Revenue Multiple Topline Rule of Thumb
1.52x Median Multiple
0.73x Low 2.31x High
AEO Direct Answer

Blood & Tissue Banks operations trade at a median 19.75x EBITDA (typical range: 15.8x – 25.68x) for middle-market platforms, and 2.8x SDE (2x – 3.8x) for owner-operated companies, with revenue multiples averaging 1.52x (0.73x – 2.31x).

2026 M&A Market Dynamics

Intense healthcare sponsor activity seeking provider platforms with clinical independence, clean Medicare/Medicaid billing audits, and scalable outpatient facility networks.

Peak Valuation Drivers

  • Payer mix stability
  • provider credentialing
  • clinical staff retention
  • and low patient concentration.

Blood & Tissue Banks Businesses We Help Sell

Our team has advised on transactions across the full range of Blood & Tissue Banks and related operations.

Blood & Tissue Banks M&A Advisor Confidential Consultation
1 Whole Blood Collection and Processing
2 Platelet Apheresis Donor Collection Services
3 Packed Red Blood Cell Component Preparation
4 Fresh Frozen Plasma and Cryoprecipitate
5 Umbilical Cord Blood Stem Cell Banking
6 Autologous and Directed Blood Donation Services
7 Donor Screening and Infectious Disease Testing
8 Blood Grouping and Antibody Identification
9 Deceased Donor Organ Recovery Coordination
10 Tissue Recovery and Allograft Processing
11 Bone and Musculoskeletal Allograft Banking
12 Cardiovascular Valve Tissue Banking
13 Cornea Eye Banking and Processing
14 Ultra-Low Temperature Liquid Nitrogen Storage
15 Courier Transport of Temperature Sensitive Blood
16 Hospital Blood Bank Inventory Management
17 FDA Biological Product Deviation Reporting
18 AABB Accredited Blood Processing Facilities
19 Perfusion Machine Organ Preservation
Image{width=800,height=600,url='https://www.aria.net/hubfs/industries/blood-and-organ-banks/aria-blood-and-organ-banks-transaction-closing-process.jpg',altText='How We Sell Your Blood & Tissue Banks Company - Transaction Closing Process',fileId=null}

How We Sell Your Blood & Tissue Banks Company

A disciplined, fully confidential process that protects your team, customers, and competitive position throughout the transaction.

1

Valuation

Comprehensive recasting of financial statements, normalization of owner compensation, evaluation of contracted client backlog, and calculation of true adjusted EBITDA.

2

CIM and Buyer-Facing Materials

Development of a confidential marketing prospectus highlighting operational procedures, customer retention metrics, and middle-management leadership.

3

Targeted Buyer Outreach

Confidentially presenting the opportunity to qualified strategic consolidators, regional operators, and vetted private equity sponsors under strict non-disclosure agreements.

4

Negotiation

Structuring competitive purchase agreements to maximize cash at closing, establish clean working capital targets, and protect the seller from post-closing liabilities.

5

Due Diligence & Closing

Managing quality of earnings audits, client contract novations, regulatory licensing assignments, and escrow disbursements to complete a successful transaction.

Recent Closed M&A Transactions

Surplus Outlet
$11,100,000
Retail / Grocery | Jul 2024
Discount supermarket with real estate located in Pennsylvania.
Metro Wireless
$4,500,000
Telecommunications | Jan 2022
Business Internet and Voice Provided located in Michigan.
Galaxy Lanes
$3,500,000
Entertainment | Dec 2024
The Konery
$3,000,000
Food Manufacturing | Mar 2025
Artisanal ice cream cone manufacturer located in New York.
Sagano Restaurants
$2,700,000
Hospitality | Jan 2026
Chain of Japanese steakhouses located in Michigan.
Anytime Fitness
$2,220,000
Health & Wellness | May 2024
Group of three fitness centers located in Michigan.
Tool Detail Corp
$1,760,000
Industrial & Manufacturing | Jan 2024
Tool precision company with real estate located in Michigan.
Irish Isle Provision Co
$1,400,000
Food Wholesale | Jun 2025
Wholesale meat and beer distributor located in Pennsylvania.
AFLS Corp
$1,380,000
Professional Services | Jan 2024
Interpretation and translation company located in Arizona.
Cribbs & Associates
Price Not Disclosed
Environmental | Jan 2025
Environmental consulting firm located in Pennsylvania
Revolution Laser Tag
Price Not Disclosed
Entertainment | Nov 2023
Family entertainment center located in Michigan.
Laura Tork Wholesale
Price Not Disclosed
Building Materials | May 2024
Building supply distributor located in Pennsylvania

Frequently Asked Questions

How are Blood & Tissue Banks businesses valued? +

Blood & Tissue Banks companies typically trade at 2.0x to 3.8x SDE for owner-operated firms or 15.8x to 25.68x+ adjusted EBITDA for scaled regional platforms, with premiums paid for verified financial records and repeat client accounts.

What makes a Blood & Tissue Banks company attractive to strategic acquirers? +

Strategic buyers prioritize favorable commercial payer mix, clean billing compliance audits, high patient retention, and mid-level provider autonomy, looking for established operational leadership that can operate without founder dependency.

How are client contracts and technical staff transferred during a sale? +

We structure assignment terms and key employee retention agreements during contract negotiations, ensuring relationships transfer smoothly to the new operating team without alerting clients prematurely.

What is the expected transition period for an owner selling a Blood & Tissue Banks company? +

Most acquirers require a 3 to 12 month transition period where the seller introduces primary corporate contacts, oversees training, and assists with operational handover.

What NAICS and SIC codes govern Blood & Tissue Banks businesses? +

Blood & Tissue Banks enterprises are categorized under NAICS Code 621991 (Blood and Organ Banks) and SIC Code 8099 (Health and Allied Services, NEC), which establish official benchmarks for banking appraisals and transaction filings.

What Aria Does Differently for Blood & Tissue Banks Business Owners

There are generalist brokers who will take your listing. Aria runs a process, and for Blood & Tissue Banks business owners, the difference shows up in the final number.

1175291 1 (7)

We Know Blood & Tissue Banks Valuations

Payer mix stability, provider credentialing, clinical staff retention, and low patient concentration. directly command top acquisition multiples.

1175291 1 (2)

Strict Confidentiality

Crew uncertainty can damage a deal fast. Our process keeps the sale confidential until you decide to disclose, helping protect operations and staff stability.

1175291 1 (4)

One Team, Start to Close

CPA, legal, M&A, real estate, and capital raising all under one roof. The same team that values your business manages the transaction through closing.

1175291 1 (5)

Access to Active Buyers

We work directly with PE-backed platforms, strategic acquirers, and institutional buyers actively acquiring blood & tissue banks companies.

Reviews from Our Clients

 

Position Your Blood & Tissue Banks Company for the Right Buyer

Aria’s Blood & Tissue Banks business advisory team prepares, markets, and negotiates Blood & Tissue Banks company business sales with institutional and strategic buyers actively acquiring in the space.

Contact us

We Close Blood & Tissue Banks Business Sales Across the Country

Aria delivers Blood & Tissue Banks M&A advisory services nationwide, with strong transaction activity across the Midwest, Mid-Atlantic, and Southeast, supporting owners in all U.S. markets.

No matter where your company is based, our team delivers nationwide M&A support.

contact-image

Contact Us to Get Started
aria-brand

michigan-map
Aria Michigan Office 127 E. 3rd Street, Suite D Rochester, MI 48307
Star 7 aria-shape-svg Star 7 BUSINESS Star 7 ADVISORS
Star 7 aria-shape-svg Star 7 BUSINESS Star 7 ADVISORS
Star 7 aria-shape-svg Star 7 BUSINESS Star 7 ADVISORS
Star 7 aria-shape-svg Star 7 BUSINESS Star 7 ADVISORS
What is your Blood & Tissue Banks business worth? Get Your Free Valuation